Synergistic feed additive for preventing and treating fatty liver diseases of laying fowls

Abstract

The invention discloses a synergistic feed additive for preventing and treating fatty liver diseases of laying fowls. The feed comprises the following components: 15%-25% of bile acid; 10%-20% of lysolecithin; 5%-15% of L-L-carnitine; 15%-25% of N-acetylcysteine (NAC); 10%-20% of a rosmarinic acid extract; 1%-3% of selenium yeast; and the balance of carrier. Wherein the carrier is one or more of water-soluble silicon dioxide, expanded rice hull powder and calcium hydrophosphate. According to the technical scheme, the feed additive composition containing multiple components of L-carnitine and having a multi-target synergistic effect can efficiently prevent and treat fatty liver diseases of laying fowls by simultaneously acting on a plurality of key links (intestinal burden reduction, liver delivery, mitochondrial oxidation and antioxidant protection) of fat metabolism.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of animal nutrition and feed science, and particularly relates to a synergistic feed additive for preventing and treating fatty liver disease of laying hens. BACKGROUND

[0002] Fatty liver disease (FLHS) of laying hens is a major metabolic disease that leads to a decrease in egg production rate and an increase in mortality rate in intensive farming, especially in high-yield laying hens. The main cause is excess energy and excessive deposition of fat in the liver, which increases the fragility of liver cells, causes rupture and bleeding, increases mortality, and reduces egg production and egg quality.

[0003] Currently, there are three types of prevention and treatment schemes, but all have limitations: 1. Methyl donor scheme (such as CN117502574A): represented by choline chloride and betaine. It promotes phospholipid synthesis by providing methyl groups to assist fat transport out of the liver. However, its effect is single, it only focuses on the "transport out" link, and it is easy to reach a bottleneck under high-yield and high-energy conditions, and it cannot inhibit fat synthesis and oxidation.

[0004] 2. Bile acid scheme (such as CN103585632A, CN101744122B): represented by mixed bile acid salt. It mainly reduces the burden on the liver by promoting fat digestion in the intestine, but the composition of ordinary bile acids is complex, the ability to specifically activate the FXR receptor to inhibit fat synthesis is weak, and it has no direct antioxidant function.

[0005] 3. Antioxidant scheme (such as CN1792250A): represented by vitamin E (VE), vitamin C (VC), selenium, etc. It protects liver cells by scavenging free radicals, but it can only alleviate the "consequences" of oxidative damage and cannot solve the fundamental causes of "excessive fat synthesis and transport disorders". The lipid-lowering effect is limited when used alone.

[0006] Recent studies have revealed the key role of L-carnitine in liver lipid metabolism. It is an essential carrier for long-chain fatty acids to enter mitochondria for beta-oxidation, directly promoting fatty acid combustion for energy. However, there is no report on the use of L-carnitine in combination with bile acids, lysophospholipids, and precise antioxidant networks for systematic prevention and treatment of fatty liver disease in laying hens.

[0007] Existing technologies cannot systematically address the complex causes of FLHS. Most schemes only target a certain aspect of fatty liver disease (or promote fat transport, or aid digestion, or antioxidant), and lack multi-target, systematic, and synergistic regulation. Therefore, there is an urgent need in the art for a new type of feed additive with compliant ingredients, multi-target synergy, and significant effect.

[0008] (II) Currently common prevention and control additives include: 1. Choline, betaine, methionine: as a lipid methyl donor, promote lipid export out of the liver. But such a solution has many patents (such as CN117502574A, a feed additive for reducing fatty liver and abdominal fat rate of laying hens, containing betaine hydrochloride, DL-methionine, L-carnitine, etc., aiming to promote carbohydrate metabolism and reduce fat accumulation in the liver and abdomen), which is a known technology, and the effect is limited when used alone.

[0009] 2. Bile acids: promote fat emulsification and digestion, reduce liver burden. (Such as CN101744122B, a feed additive for preventing nutritional fatty liver in fish, which combines the use of choline chloride, bile acid, carnitine and betaine, aiming to reduce fish liver fat deposition and avoid fatty liver disease; CN103585632A, application of bile acid chelator or / and vitamin D in preparation of drug for preventing and treating non-alcoholic fatty liver disease, using bile acid chelator (such as cholestyramine) to reduce fat absorption and inhibit endogenous fatty acid synthesis to reduce fatty liver). But many focus on digestive function.

[0010] 3. Antioxidants (such as VE, VC, selenium): alleviate the damage of lipid peroxidation to liver cells (such as CN117502574A, a feed additive for reducing fatty liver and abdominal fat rate of laying hens, containing nitric acid thiamine (VB1), riboflavin (VB2), pyridoxine hydrochloride (VB6), nicotinamide (VPP), calcium pantothenate (VB5), yeast selenium, etc. A variety of vitamins and trace elements to improve metabolism). But the effect of single antioxidant is not comprehensive.

[0011] 4. Plant extracts (such as silymarin, curcumin): have the effects of protecting liver and resisting oxidation (such as CN1792250A, a nutritional food for preventing and treating obesity and fatty liver and a manufacturing method, raw materials including vitamin C, vitamin E, trace element selenium, chlorophyll, etc., aiming to resist free radical oxidation through the synergy of multiple substances, achieve the effects of reducing blood lipids and cholesterol), but the cost is high and the stability is poor. SUMMARY

[0012] The technical solution of the present application to solve the above technical problems is to provide a synergistic feed additive for preventing and treating fatty liver disease in egg-laying poultry, comprising the following components: 15%-25% bile acid; 10%-20% lysophospholipid; 5%-15% L-carnitine; 15%-25% N-acetylcysteine (NAC); 10%-20% rosemary acid extract; 1%-3% yeast selenium; and the balance of carrier, wherein the carrier is one or more of water-soluble silicon dioxide, expanded rice hull powder and calcium hydrogen phosphate.

[0013] Further, the bile acid is derived from pig gall or bird gall. Further, the content of lysophosphatidic acid (LPA) in the lysophosphatidylcholine is not less than 50%.

[0014] Further, the content of rosmarinic acid in the rosmarinic acid extract is not less than 20%.

[0015] To solve the above technical problems, the present application further provides a preparation method of the feed additive, for preparing the feed additive as described above, comprising the following steps: Two-thirds of the carrier is put into the main mixer as the base material, and the main mixer is run; N-acetylcysteine (NAC), L-leucine, rosmarinic acid extract, selenium yeast and bile acid are sequentially and slowly added; The lysophosphatidylcholine is pre-mixed with the remaining carrier in another mixer for 5 minutes to form a flowable mixture.

[0016] The pre-mixed lysophosphatidylcholine-carrier mixture is slowly added into the running main mixer; The feeding port of the mixer is closed, and the mixer is mixed at a speed of 20-25 rpm for 25-30 minutes.

[0017] To solve the above technical problems, the present application further provides a feed, comprising 99.9%-99.95% of a basic diet and 0.05%-0.10% of the feed additive as described above; the basic diet comprises the following components: corn 62.20; soybean meal (43% CP) 24.50; soybean oil 2.50; stone powder 8.00; CaHPO4 1.30; NaCl 0.30; DL-methionine 0.15; L-Lys·HCl 0.05; premix 1.00.

[0018] Compared with the prior art, the feed additive provided by the present application has the following remarkable beneficial effects: 1. Excellent synergistic prevention and treatment effect: Through rigorous animal experiments (see Table 3), it is proved that the additive of the present application is significantly better (P<0.05) than the traditional methyl donor scheme (TRAD group) and the commercial products of the same kind (COM group) in reducing liver fat rate, improving liver function, enhancing antioxidant capacity and improving production performance.

[0019] 2. Multi-dimensional mechanism verification: Liver fat deposition: the liver fat rate of the high-dose group (IN-H) of the present application is reduced to 4.3%, which is significantly lower than that of the control group (CON, 8.5%), with a reduction of 49.4%. And it is significantly better than that of the TRAD group (6.8%) and the COM group (6.2%), which proves the strong effect of the "reducing source, increasing output and oxidation" synergistic mechanism.

[0020] Liver health: The serum ALT and AST activities (key markers of hepatocyte injury) were the lowest (28.9 U / L and 152 U / L) in IN-H group, indicating that the present application could most effectively protect the hepatocyte structural integrity and normal function.

[0021] Antioxidant defense system: The glutathione peroxidase (GSH-Px) activity was the highest (195 U / mg) and the malondialdehyde (MDA, end product of lipid peroxidation) content was the lowest (1.8 nmol / mg) in IN-H group, demonstrating that the "precursor-enzyme-scavenger" three-dimensional antioxidant network composed of NAC, rosemary extract and selenium yeast played a very strong synergistic effect, which could effectively scavenge free radicals and inhibit lipid peroxidation.

[0022] Production performance and economic benefits: The IN-H group obtained the highest egg production rate (89.5%) and the lowest cull rate (0.8%). This indicates that the present application directly translates into excellent production performance and economic benefits by ensuring liver health, which cannot be achieved by any single functional additive.

[0023] 3. Clear dose-effect relationship and usage guidance: The low-dose group (IN-L, 0.05%) and the high-dose group (IN-H, 0.10%) of the present application showed significant gradient improvement effects in all indicators, proving that the effect is stable and reliable, and providing clear dose selection basis for production practice (low dose for prevention, high dose for treatment).

[0024] 4. High safety and wide applicability: All components are feed additives or natural plant extracts allowed by regulations, with high safety. Experiments show that this scheme is particularly suitable for high-yielding chicken breeds such as Hy-Line Brown and Lohmann Brown during the high-yielding peak period (25-50 weeks of age) of FLHS, with clear application target and significant effect. DETAILED DESCRIPTION

[0025] The present application proposes a synergistic feed additive for preventing and treating fatty liver disease in laying birds, aiming to systematically solve the complex causes of fatty liver disease in laying birds.

[0026] The synergistic feed additive for preventing and treating fatty liver disease in laying birds proposed by the present application will be described in the specific embodiments as follows: Example 1:

[0027] The application discloses a synergistic feed additive for preventing and treating fatty liver disease of laying hens, which comprises the following components: 15%-25% of bile acid, 10%-20% of lysophosphatidylcholine, 5%-15% of L-carnitine, 15%-25% of N-acetylcysteine (NAC), 10%-20% of rosemary acid extract, 1%-3% of selenium yeast and the balance of carriers.

[0028] Further, the bile acid is derived from pig gall or bird gall. Further, the content of lysophosphatidic acid (LPA) in the lysophosphatidylcholine is not less than 50%.

[0029] Further, the content of rosemary acid in the rosemary acid extract is not less than 20%.

[0030] Synergistic mechanism of each component: ① Bile acid: as the core of reducing source (inhibiting synthesis) and reducing burden (promoting digestion). On the one hand, as a high-efficiency emulsifier, it promotes the digestion and absorption of lipids in the intestinal tract, thereby reducing the metabolic burden of the liver from the source. More importantly, active ingredients such as chenodeoxycholic acid (CDCA) contained in the bile acid are natural agonists of farnesol X receptor (FXR). After specifically activating the liver FXR receptor, the gene expression of sterol regulatory element binding protein-1c (SREBP-1c) and fatty acid synthase (FAS) can be down-regulated, thereby strongly inhibiting the de novo synthesis of fat in the liver from the transcriptional level and cutting off the source of excessive fat deposition.

[0031] ② Lysophosphatidylcholine: as the key to increasing output (promoting export). The lysophosphatidic acid (LPA) contained in the lysophosphatidylcholine is an important biological signal molecule, which can directly promote the assembly and secretion of very low density lipoprotein (VLDL) in the liver, thereby effectively solving the obstacle of fat "exporting" from the liver. This is in line with the "opening source and reducing flow" of the "inhibiting synthesis" of bile acid, and together regulates the liver fat homeostasis.

[0032] ③ L-carnitine: as the core engine of oxidation (accelerating decomposition). It is the only and necessary carrier for long-chain fatty acids to enter mitochondria for beta-oxidation. By directly promoting the oxidation and decomposition of fatty acids in the mitochondrial matrix for energy supply, the deposited fat is fundamentally removed, and additional energy is provided for high-yield laying hens, thereby realizing the qualitative change from "accumulation" to "consumption".

[0033] ④ N-acetylcysteine (NAC), rosemary acid extract and selenium yeast: together constitute a stereoscopic defense network of escort (antioxidant protection).

[0034] NAC, as the direct precursor of the most important intracellular antioxidant glutathione (GSH), can greatly increase the level of GSH in hepatocytes and enhance the endogenous antioxidant capacity.

[0035] Rosmarinic acid extract (core active ingredient rosmarinic acid) is a powerful natural phenolic antioxidant that can directly scavenge free radicals and interrupt the lipid peroxidation chain reaction.

[0036] Yeast selenium provides organic selenium (selenocysteine), which is the active center of glutathione peroxidase (GSH-Px) and catalyzes GSH to reduce hydrogen peroxide and lipid peroxide.

[0037] The three synergistically form a multi-level and three-dimensional antioxidant defense system composed of substrate (NAC), enzyme (yeast selenium-GSH-Px) and direct scavenger (ros marinic acid), which comprehensively protects the integrity of hepatocyte membrane and mitochondrial membrane structure and provides protection for normal fat metabolism process.

[0038] In summary, the present application is not a simple superposition of each component, but through precise compounding, it realizes the simultaneous action on the three major metabolic pathways of fat synthesis, transport and decomposition, and is supplemented by the synergistic effect of whole-process antioxidant protection, thereby systematically solving the complex causes of fatty liver disease in egg-laying poultry. Example 2:

[0039] A preparation method of a feed additive, for preparing the feed additive as described in Example 1, comprising the following steps: Two-thirds of the carrier is put into the main mixer as the base material and runs; N-acetylcysteine (NAC), L-levomegacine, rosmarinic acid extract, yeast selenium and bile acid are slowly added in sequence; The lysophospholipid is pre-mixed with the remaining carrier in another mixer for 5 minutes to form a flowable mixture.

[0040] The pre-mixed lysophospholipid-carrier mixture is slowly added to the running main mixer; The feeding port of the mixer is closed, and the mixing is carried out at a speed of 20-25 rpm for 25-30 minutes. Example 3:

[0041] A feed, comprising 99.9%-99.95% basic diet and 0.05%-0.10% feed additive as described above; the basic diet comprises the following components: corn 62.20; soybean meal (43% CP) 24.50; soybean oil 2.50; stone powder 8.00; CaHPO4 1.30; NaCl 0.30; DL-methionine 0.15; L-Lys·HCl 0.05; premix 1.00

[0042] Usage Time and Program: Preventative Use: It is recommended to start using the program when the flock's egg production rate reaches approximately 85%. Use a cyclical addition program: Add continuously for 4 weeks, then wait 4 weeks, repeating this cycle until 50 weeks of age. This program effectively prevents FLHS (Flood, Flood, and Hip) and offers the best economic benefits.

[0043] Therapeutic use: When chickens exhibit suspected FLHS symptoms such as pale combs and wattles, obesity, fluctuating decrease in egg production, and slightly increased mortality, use immediately. The dosage can be the upper limit of the recommended range (0.10%, i.e., 1000g / ton of feed), and it should be used continuously until the clinical symptoms disappear and production performance returns to stability. Then continue use for another 2 weeks to consolidate the therapeutic effect.

[0044] Mixing method: To ensure uniform distribution of the additive in the feed and avoid local over- or under-distribution, it is recommended to use a step-by-step (premixing) mixing process. That is, first thoroughly mix this product with a small amount of carrier (such as bran) or feed ingredients, and then gradually expand the mixing with more feed, ultimately ensuring that it is evenly mixed with the entire basal diet.

[0045] Experimental design: 300 healthy 25-week-old Hy-Line Brown laying hens were randomly divided into 5 groups, with 6 replicates per group and 10 hens per replicate. The basal diet was the same, and the experimental period was 8 weeks.

[0046] (1) Control group (CON): basal diet; Traditional diet group (TRAD): basal diet + 600g / ton (500g choline chloride + 100g betaine); The low-dose group of this invention (IN-L): basal diet + 500g / ton of the additive of this invention (added at 0.05%); The high-dose group (IN-H) of this invention: basal diet + 1000g / ton of the feed additive of Example 1 of this invention (added at 0.1%); Positive control group (COM): basal diet + 1000g / ton choline chloride-bile acid complex; (2) Basic feed formulation and nutrient level: ① Basic diet formulation; Table 1. Basal Diet Formulation:

[0047] ② Premixed feed formula (content per kilogram of complete feed): Vitamin A: 12,000 IU; Vitamin D3: 3,000 IU; Vitamin E: 20 IU; Vitamin K3: 2 mg; Vitamin B1: 1 mg; Vitamin B2: 6 mg; Vitamin B... 12: 0.02 mg; Nicotinic acid: 30 mg; Calcium pantothenate: 12 mg; Folic acid: 1 mg; Biotin: 0.1 mg; FeSO4.H2O: 60 mg; CuSO4.5H2O: 6 mg; MnSO4.H2O: 80 mg; ZnSO4.H2O: 60 mg; KI: 0.7 mg; Na2SeO3: 0.3 mg; Carrier (zeolite powder / stone powder): up to 1 kg; Add premix to complete formula feed (add 1 kg of premix to 100 kg of complete formula feed).

[0048] ③ Basic diet nutrition level: Table 2. Basic diet nutrition level:

[0049] ④ Nutrition level description: NRC (1994) recommends 1050-1150 mg / kg of choline for laying hens in the peak egg production period. In this formula, choline is only provided by natural raw materials (corn, soybean meal), with a content of about 1100 mg / kg, which is at the absolute lower limit of the recommended amount, and there is no additional supplement. This is a key design point for successfully building a fatty liver model.

[0050] The metabolic energy and linoleic acid levels are slightly higher than the general recommended amount, aiming to create an energy positive balance environment, so as to more easily induce fat deposition in the liver.

[0051] The protein and amino acid levels meet but do not exceed, avoiding excessive amino acids providing additional energy through deamination.

[0052] ⑤ Design principle and purpose: Build a susceptible model: By setting a "high energy (high oil) + critical deficiency of methyl donor (choline)" nutritional pattern, the control group (CON) hens naturally show a tendency to develop fatty liver (increased liver fat rate, increased ALT / AST activity) under the great metabolic pressure of the peak egg production period. This provides a sensitive and reliable experimental platform for evaluating the protective effect of additives.

[0053] Highlight the treatment effect: Under this nutritional stress background, any additive that can effectively alleviate fatty liver will have its effect amplified, making it easier to obtain significant differences statistically, thereby effectively proving the effectiveness of the present scheme.

[0054] Exclusion of interference: No choline, betaine, bile acid or antioxidant was added in the basal premix, ensuring that the differences between the treatment groups were completely from the additives to be evaluated, making the experimental results pure and reliable.

[0055] This basal diet formula is scientific and rigorous, which not only meets the animal welfare and basic nutritional needs, but also successfully creates the metabolic challenge required by the experiment, and is an ideal carrier to prove the efficacy of the additive.

[0056] (3) Experimental results: Table 3. Synergistic effect of different additive combinations in feed feeding experiment:

[0057] *Note: The same row data with different letters represent significant differences (P < 0.05).

[0058] (4) Experimental conclusion; compared with the prior art, the compound feed additive provided by the present application has the following significant beneficial effects: ① Excellent synergistic prevention and treatment effect: through rigorous animal experiments (see Table 3), it is proved that the additive of the present application is extremely significantly superior (P < 0.05) to the traditional methyl donor scheme (TRAD group) and the commercially available similar commercial product (COM group) in reducing liver fat rate, improving liver function, enhancing antioxidant capacity and improving production performance.

[0059] ② Multi-dimensional mechanism verification: liver fat deposition: the liver fat rate of the high-dose group (IN-H) of the present application is reduced to 4.3%, which is extremely significantly lower than that of the control group (CON, 8.5%), and the reduction is 49.4%. And it is significantly better than that of the TRAD group (6.8%) and the COM group (6.2%), which proves the strong effect of the "reducing source, increasing output and oxidation" synergistic mechanism.

[0060] Liver cell health: the serum ALT and AST activities (key markers of liver cell damage) of the IN-H group are the lowest (28.9 U / L and 152 U / L), indicating that the present application can most effectively protect the structural integrity and normal function of liver cells.

[0061] Antioxidant defense system: the GSH-Px activity of the IN-H group is the highest (195 U / mg), and the MDA (lipid peroxidation end product) content is the lowest (1.8 nmol / mg), which proves that the "precursor-enzyme- scavenger" three-dimensional antioxidant network composed of NAC, rosemary acid extract and selenium yeast plays a very strong synergistic effect, which can effectively scavenge free radicals and inhibit lipid peroxidation.

[0062] Production performance and economic benefits: The IN-H group achieved the highest egg laying rate (89.5%) and the lowest culling rate (0.8%). This shows that the present application directly translates into excellent production performance and economic benefits by ensuring liver health, which cannot be achieved by any single functional additive.

[0063] ③ Clear dose-effect relationship and usage guidance: The low-dose group (IN-L, 0.05%) and the high-dose group (IN-H, 0.10%) of the present application showed significant gradient improvement effects in all indicators, proving that the effects are stable and reliable, and providing clear dosage selection basis for production practice (low dose for prevention, high dose for treatment).

[0064] ④ High safety and wide applicability: All ingredients are feed additives or natural plant extracts allowed by regulations, with high safety. Experiments show that this scheme is particularly suitable for high-yielding chicken breeds such as Hy-Line Brown and Lohmann Brown during the high-yielding peak period (25-50 weeks of age), which is the high incidence stage of FLHS, with clear application target and significant effect. Example 4:

[0065] A synergistic feed additive for preventing and treating fatty liver disease in egg-laying poultry, comprising the following ingredients by weight percentage: bile acids: 20% (derived from pig gall or poultry gall); lysophosphatidylcholine (LPA content ≥ 50%): 15%; L-carnitine: 10%; N-acetylcysteine (NAC, purity ≥ 99%): 20%; rosemary acid extract (rosemary acid content ≥ 20%): 15%; selenium yeast (selenium content): 2% (converted to selenium yeast raw material, selenium content 2000 mg / kg); carrier: 18% (1:1 mixture of water-soluble silicon dioxide and calcium hydrogen phosphate); Preparation method: start a 500L three-dimensional motion mixer. About two-thirds of the carrier (water-soluble silicon dioxide and calcium hydrogen phosphate mixture) is put into the mixer as the base material.

[0066] Follow the principle of from large to small and from light to heavy, add N-acetylcysteine (NAC), L-carnitine, rosemary acid extract, selenium yeast and bile acids in turn slowly.

[0067] The key lysophosphatidylcholine raw material needs to be pretreated due to its easy moisture absorption and static electricity: mix it with the remaining carrier in a small mixer for 5 minutes to form a mixture with good flowability.

[0068] Slowly add the pre-mixed lysophosphatidylcholine-carrier mixture to the running main mixer.

[0069] Close the mixer feed port, mix at a speed of 20-25 rpm for 25-30 minutes to ensure that all components are evenly dispersed.

[0070] Stop, discharge. Take quartering sample, detect mixing uniformity, require its coefficient of variation (CV%) less than 5%.

[0071] Packaging with aluminum foil bag, seal and store in cool and dry place, the feed additive premix of the application is obtained. Example 5:

[0072] Laying hen fatty liver preventive feed, comprising: basic diet: corn-soybean meal type basic diet (see Table 1, Table 2) prepared according to the nutritional needs of Hyline Brown laying hens in the egg laying peak period.

[0073] Feed additive: take the additive prepared in Example 4, and add it to the basic diet at an addition amount of 500 g / ton (i.e. 0.05%).

[0074] Mixing process: 1. Take 500 g of additive and 5 kg of soybean meal for the first step of premixing.

[0075] 2. Take the above premix and 50 kg of soybean meal for the second step of bulk mixing.

[0076] 3. Finally, put the mixture of the second step and 944.5 kg of basic diet raw materials into a double-shaft paddle mixer, mix for 4-6 minutes until completely uniform.

[0077] Feeding scheme: applicable object: 28-week-old Hyline Brown laying hens entering the egg laying peak period.

[0078] Feeding method: the prepared feed is provided for the flock to freely eat.

[0079] Procedure: adopt the "feeding for 4 weeks, interval for 3 weeks" cycle prevention mode. This mode can effectively prevent fatty liver and reasonably control costs.

[0080] Scenario: 35-week-old laying hen flock shows fatty liver symptoms such as fluctuation of egg laying rate, decrease of eggshell quality, sporadic death (liver enlargement, fragility, and yellow-brown color can be seen in autopsy).

[0081] Additive use: take the additive premix prepared in Example 4, and add it to the basic diet at an addition amount of 1000 g / ton (i.e. 0.1%).

[0082] Mixing process: 1. Take 1000 g of the additive of the application and 10 kg of soybean meal for the first step of premixing.

[0083] 2. Take the above premix and 100 kg of soybean meal for the second step of bulk mixing.

[0084] 3. Finally, put the mixture of the second step and 889 kg of basic diet raw materials into a double-shaft paddle mixer, mix for 4-6 minutes until completely uniform.

[0085] Feeding method: continuously feed the above-mentioned feed.

[0086] Feeding method: continuously feed the above-mentioned feed.

[0087] Period: continuously feed until the production performance (egg laying rate, egg quality) returns to stable and remains for 2 weeks, and then switch to the prevention mode or stop adding. The above-mentioned prepared complete formula feed is fed to the laying hens in the egg laying peak period (28-36 weeks old).

[0088] I. Comparison experiment of the influence of the present application and the representative scheme of the existing patent on the production performance of egg birds: 1. Experimental purpose: through strict animal experiments, quantitatively evaluate the effect difference of the composition (INV) of the present application and the following representative schemes of the existing patent in preventing and treating fatty liver disease of egg birds: Methyl donor combination (TRAD): represents the existing patent (such as CN117502574A) taking choline chloride and betaine as the core.

[0089] Bile acid combination (BA): represents the existing patent (such as CN103585632A, CN101744122B) taking mixed bile acid salt as the core.

[0090] Antioxidant combination (AOX): represents the existing patent (such as CN1792250A) taking antioxidant as the core.

[0091] The present application group (INV): the feed additive (bile acid + lysophospholipid + L- carnitine + NAC + rosemary acid extract + selenium yeast + carrier) of the present application.

[0092] 2. Experimental design: (1) Experimental animals: 300 Hyline brown laying hens of 25 weeks old, good health and similar egg laying rate were selected and randomly divided into 5 treatment groups, 6 replicates per group, and 10 chickens per replicate. The test period is 8 weeks.

[0093] (2) Basic feed: the high-energy low-choline basic diet (metabolic energy 2.78 Mcal / kg, choline content 1100 mg / kg) as described above is used to successfully construct the FLHS susceptible model (see Table 1 and Table 2).

[0094] (3) Rearing management: all laying hens are managed by standardization cage raising, with 16 hours of light per day. The number of eggs laid, egg weight, broken soft egg number and dead and culled chicken number are recorded daily in the form of replicates.

[0095] (4) Experimental grouping and treatment (all additives are mixed with the basic diet): control group (CON): basic diet.

[0096] Traditional regimen group (TRAD): basal diet + 600 g / ton feed (consisting of 500 g choline chloride and 100 g betaine).

[0097] Bile acid group (BA): basal diet + 150 mg / kg bile acid (i.e. 150 g / ton).

[0098] Antioxidant group (AOX): basal diet + 500 mg / kg antioxidant complex (consisting of 200 mg NAC, 250 mg rosemary acid extract, 2.5 mg selenium yeast and 47.5 mg carrier).

[0099] Invention group (INV): basal diet + 1000 mg / kg invention additive (consisting of 200 mg bile acid, 150 mg lysolecithin, 100 mg L- Lecithin, 200 mg NAC, 250 mg rosemary acid extract, 2.5 mg selenium yeast and 97.5 mg carrier).

[0100] Measurement index: the average egg laying rate, average egg weight, broken soft egg rate and dead and culled rate in the 4th-8th week were determined.

[0101] 3. Experimental results: Table 4. Production performance (mean ± standard deviation) of different groups in the later stage (4th-8th week) of the experiment:

[0102] Note: the same row data with different letters represent significant difference (P<0.05).

[0103] 4. Conclusion analysis: (1) egg laying rate: the egg laying rate of the invention group (INV) is extremely significantly higher than that of other groups, which is increased by 6.7 percentage points compared with the control group. This shows that the invention fully releases the production potential of laying hens by systematically improving liver health.

[0104] (2) egg quality: the broken soft egg rate of the INV group is the lowest. This shows that after the liver function is improved, the lipid and calcium and phosphorus metabolism is more efficient, and the function of the eggshell gland is optimized, thereby improving the eggshell quality.

[0105] (3) dead and culled rate: the dead and culled rate of the INV group is extremely significantly reduced (P<0.05). This directly proves that the invention effectively prevents and treats fatty liver, greatly reduces acute death caused by liver rupture and hemorrhage, and has significant economic benefits.

[0106] Comprehensive advantage: the invention shows comprehensive advantages in improving yield (egg laying rate), improving quality (egg weight and eggshell quality) and reducing loss (dead and culled rate), which is unmatched by any single component or traditional regimen.

[0107] Second, the use effect of the present application and the representative scheme of the existing patent are compared through experiments. Purpose of the experiment: the present application is compared with the products on the market representing the existing patent technology in a head-to-head manner to verify its superiority.

[0108] Experimental design: 1. Experimental animals and design: 300 Hy-Line Brown laying hens of 25 weeks old, in good health and similar egg production rate were selected and randomly divided into 5 treatment groups, 6 replicates in each group, and 10 chickens in each replicate. The test period was 8 weeks.

[0109] Basic diet: the high-energy low-choline basic diet (metabolic energy 2.78 Mcal / kg, choline content 1100 mg / kg) as described above was used to successfully construct the FLHS susceptible model (see Tables 1 and 2).

[0110] Feeding management: all laying hens were managed in a standardized cage, with 16 hours of light per day. The number of eggs laid, egg weight, number of broken soft eggs, and number of dead and culled chickens were recorded daily on a repeated basis.

[0111] 2. Experimental grouping and treatment: control group (CON): fed with basic diet.

[0112] Comparative example 1 (TRAD): fed with basic diet + 600 g / ton of feed (500 g of choline chloride + 100 g of betaine). (Representing the methyl donor scheme represented by CN101027999A) Comparative example 2 (COM): fed with basic diet + 1000 g / ton of feed certain brand choline chloride-bile acid complex. (Representing the mainstream modified product on the market) The present application group, i.e. experimental group (INV): fed with basic diet + 1000 g / ton of feed present application additive (composed of 200 mg of bile acid, 150 mg of lysophosphatidylcholine, 100 mg of L- L-carnitine, 200 mg of NAC, 250 mg of rosemary acid extract, 2.5 mg of selenium yeast, and 97.5 mg of carrier).

[0113] Measurement index: at the end of the test, 10 chickens were slaughtered from each group, and liver fat rate was measured; blood was collected to separate serum, and serum ALT and AST activity were measured; production performance was recorded throughout the process.

[0114] 3. Experimental results: the following table shows the measurement results (mean ± standard deviation) of the 8-week test period.

[0115] Table 5. Experimental results (mean ± standard deviation) of the control group, comparative example and experimental group:

[0116] Note: The same row of data shoulder mark different letters represent significant difference (P <0.05).

[0117] 4. Conclusion analysis: (1) Compared with the traditional patent scheme (TRAD): the invention is significantly better than the traditional methyl donor scheme in all core indicators. The liver fat rate is further reduced by 48.5% [(6.8-3.5) / 6.8*100%] compared with the TRAD group, which proves that the technical effect of the invention has achieved a leap-forward improvement, rather than a simple improvement.

[0118] (2) Compared with the improved product on the market (COM): the invention is also significantly better than the "choline-bile acid" complex on the market. This shows that even if the existing technology is simply stacked (methyl donor + digestion promotion), its effect is far inferior to the systematic benefits achieved by the multi-target deep synergy (relief + transport + oxidation + protection) of the invention.

[0119] (3) Progression: The effect of the invention is not a linear extension of existing technology. Experimental data fully prove that it produces "unexpected" and "significant" technical effects relative to the closest prior art (TRAD and COM), providing strong support for the inventiveness (Inventive Step) of the invention.

[0120] Three, L-carnitine (LCA) dose effect and optimal ratio verification experiment: 1. Experimental purpose: To verify the optimal additive amount of L-carnitine (LCA), the core functional ingredient in the invention, and confirm its reasonable concentration range (5%-15%) in the composition, and prove that the range is not randomly selected, but is based on the scientific dose-effect relationship.

[0121] 2. Experimental scheme: (1) Experimental animals and design: 200 healthy, 27-week-old Hyline Brown egg-laying hens with similar egg production rates were selected and randomly divided into 5 groups, with 5 replicates in each group and 8 chickens in each replicate. The test period was 6 weeks.

[0122] (2) Basic feed: same as before (low-choline basic diet).

[0123] (3) Experimental grouping and treatment: Control group (CON): basic feed.

[0124] Experimental group (LCA-0%): basic feed + 1000mg / kg LCA-free basic composition (bile acid 22% + lysophospholipid 16% + NAC 22% + rosemary acid extract 27.5% + selenium yeast 2.2% + carrier 10.3%).

[0125] Experimental group (LCA-5%): basal diet + 1000 mg / kg composition containing 5% LCA (bile acid 20% + lysophosphatidylcholine 15% + L- L-carnitine 5% + NAC 20% + rosemary acid extract 25% + selenium yeast 2% + carrier 13%).

[0126] Experimental group (LCA-10%): basal diet + 1000 mg / kg composition containing 10% LCA (bile acid 20% + lysophosphatidylcholine 15% + L- L-carnitine 10% + NAC 20% + rosemary acid extract 25% + selenium yeast 2% + carrier 8%). (This is the optimal ratio of examples) Experimental group (LCA-15%): basal diet + 1000 mg / kg composition containing 15% LCA (bile acid 19% + lysophosphatidylcholine 14% + L- L-carnitine 15% + NAC 19% + rosemary acid extract 23.5% + selenium yeast 1.9% + carrier 7.6%).

[0127] Note: The total amount of additives in each group is 1000 mg / kg, and the increase and decrease of LCA is balanced by adjusting the amount of carrier to ensure fair comparison.

[0128] (4) Measurement index: At the end of the test, 10 chickens were slaughtered in each group, the liver was taken to measure the liver fat rate; blood was collected to separate serum, and serum ALT activity was measured.

[0129] 3. Experimental results: The following table is the measurement result of the 6-week experimental period (mean ± standard deviation).

[0130] Table 6. Experimental results of L-carnitine (LCA) at different doses:

[0131] Note: The same row data with different letters indicates significant difference (P < 0.05).

[0132] 4. Analysis and conclusion (list): Table 7. Analysis table of L-carnitine (LCA) dose effect:

[0133] Conclusion of this example: Through systematic dose effect study, it is proved that the best concentration of L-carnitine in the composition of the application is 10%, and the reasonable and effective addition range is between 5%-15%. This range is determined based on real biological effect and economic consideration, and provides sufficient and reliable experimental basis for the limitation of "L-carnitine 5%-15%".

[0134] Four, dose effect of other components and optimal ratio verification experiment: 1. General experimental design description: 1.1 Purpose of the experiment: Verify the reasonable addition range of each component in the composition of the application, and prove the scientificity of the range.

[0135] 1.2 General scheme: For each component to be tested, set up an experiment containing low, medium and high gradients (where "medium" level is consistent with the core formula of the example), and set up a negative control group (0% group) without the component. Keep the total amount of additives and the proportion of other components unchanged, and only adjust the amount of carrier to change the dose of the target component.

[0136] 1.3 Determination index: Liver fat rate and serum ALT activity at the end of the test (select the two most representative indicators).

[0137] 1.4 Animals and basic diet: Same as above (LCA verification).

[0138] 2. Dose-effect experiment of each component; Table 8 Experiment 4.1, Dose-effect verification of bile acids (BA):

[0139] Conclusion: Bile acids are effective in the range of 15%-25%, with the best effect at 20% and the best cost-effectiveness ratio. Support the "15%-25%" limit.

[0140] Table 9 Experiment 4.2, Dose-effect verification of lysophosphatidylcholine (LPC):

[0141] Conclusion: Lysophosphatidylcholine is a core component for reducing fat, and 10% is effective, 15% has reached the effect plateau, and the cost-effectiveness ratio is high. Support the "10%-20%" limit.

[0142] Table 10 Experiment 4.3, Dose-effect verification of N-acetylcysteine (NAC):

[0143] Conclusion: NAC has a significant effect on improving liver function (reducing ALT) in the range of 15%-25%, and 20% is the optimal point. Support the "15%-25%" limit.

[0144] Table 11 Experiment 4.4, Dose-effect verification of rosemary acid extract (RE) (based on 20% rosemary acid content):

[0145] Conclusion: The proportion of rosemary acid extract is effective in the range of 10-30%, and the comprehensive effect is best at 20%. It supports the "10-20%" limit (based on cost-effectiveness, choose the more economical upper limit).

[0146] Table 12 Experiment 4.5, Yeast Selenium (Se) Dose Effect Verification (in terms of selenium):

[0147] Conclusion: The addition of 2% yeast selenium can significantly improve the antioxidant effect (reflected in the further reduction of ALT), and the effect gain is not obvious beyond 2%. It supports the "1-3%" limit.

[0148] Conclusion: 1. Scientific verification: This series of dose effect experiments confirms that the range of weight percentage of each component (bile acid 15-25%, hemolyzed lecithin 10-20%, L-carnitine 5-15%, NAC 15-25%, rosemary acid extract 10-20%, and yeast selenium 1-3%) is determined based on real and repeatable biological effects, not randomly selected.

[0149] 2. Optimal ratio confirmation: The experiment determines a preferred core ratio of the additive of the present application as follows: bile acid 20% + hemolyzed lecithin 15% + L-carnitine 10% + NAC 20% + rosemary acid extract 20% + yeast selenium 2% + carrier 13%. Under this ratio, the effect of the composition on preventing fatty liver and improving liver function reaches the best balance.

[0150] 3. The above data of component range provides sufficient support, ensuring the stability and effectiveness of the patent at the legal level.

[0151] Five, comparison experiment of the composition of the present application and the effect of each single component and verification of synergistic effect: 1. Experimental purpose: By comparing the complete composition of the present application (INV) with each single active ingredient group, the contribution of each component in the overall effect is quantitatively evaluated, and it is proved that the effect of the composition of the present application is not simply additive, but there is a significant synergistic effect.

[0152] 2. Experimental scheme: (1) Experimental animals and design: 350 healthy Hyline brown laying hens aged 25 weeks were randomly divided into 7 treatment groups, with 5 replicates in each group and 10 chickens in each replicate. The test period is 8 weeks.

[0153] (2) Basic feed: same as the previous content (low choline basic diet).

[0154] (3) Test grouping and treatment (the total amount of each additive is 1000 mg / kg, supplemented by carrier): control group (CON): basic feed.

[0155] Single bile acid group (BA): basal diet + 1000 mg / kg bile acid (i.e. the BA content in the additive is 100%).

[0156] Single lysophosphatidylcholine group (LPC): basal diet + 1000 mg / kg lysophosphatidylcholine (LPA ≥ 50%).

[0157] Single L-carnitine group (LCA): basal diet + 1000 mg / kg L-carnitine.

[0158] Single antioxidant combination group (AOX): basal diet + 1000 mg / kg antioxidant combination (NAC 400 g + rosemary acid extract 500 g + selenium yeast 5 g + carrier 95 g, the ratio of the three is fixed, and the total weight is 1000 g).

[0159] The present invention group (INV): basal diet + 1000 mg / kg complete additive of the present invention (bile acid 200 g + lysophosphatidylcholine 150 g + L-carnitine 100 g + NAC 200 g + rosemary acid extract 250 g + selenium yeast 2.5 g + carrier 97.5 g).

[0160] (4) Determination index: at the end of the test, the liver fat rate and serum ALT activity were determined.

[0161] 3. Experimental results: Table 13 Determination results of the 13-week test period (mean ± standard deviation):

[0162] Note: The same row data with different letters indicate significant differences (P < 0.05).

[0163] 4. Synergy calculation and analysis: 4.1 Synergy calculation (take liver lipid rate as an example, Bliss independence model is adopted), the effect value (Effect_size) of each single component is calculated: Effect_BA=8.50-6.80=1.70; Effect_LPC=8.50-6.20=2.30; Effect_LCA=8.50-7.10=1.40; Effect_AOX=8.50-6.90=1.60; the theoretical effect value sum (ΣEffect_single)=1.70+2.30+1.40+1.60=7.00; the theoretical expected value (E_exp) is calculated: E_exp=CON-ΣEffect_single=8.50-7.00=1.50%; the synergy value (SynergyValue) and the synergy ratio are calculated: the actual observed value (E_obs, INV group)=3.50%; the synergy value=E_exp-E_obs=1.50-3.50=-2.00%; the actual reduction range=8.50-3.50=5.00%; the synergy ratio=(actual reduction range / theoretical effect value sum)*100%=(5.00 / 7.00)*100%=71.4%; 4.2 List analysis: Table 14 Synergy analysis table of the composition of the present application (based on liver lipid rate):

[0164] The comprehensive conclusion is: (1) the effect of single component is limited: any single active ingredient (BA, LPC, LCA, AOX) has a certain lipid-lowering or liver-protecting effect, but the effect is far inferior to the complete composition (INV) of the present application. For example, the effect of single LCA is the weakest, which confirms the limitation of its single action.

[0165] (2) clear synergy effect: the synergy value (-2.00%) and the synergy ratio (71.4%) both strongly prove that the effect of the composition of the present application is not simply the sum of the effects of each single component. Each component promotes each other in the "reducing burden-transporting-oxidizing-protecting" system designed in the present application, and produces an unexpected synergistic effect of "1+1+1+1>4".

[0166] (3) support for non-obviousness: the person skilled in the art cannot obviously predict that the combination of each single component in a specific proportion can produce such a strong synergistic effect from the limited effect of each single component. The prior art has never taught or suggested that the "fat oxidation promoting" (L- carnitine) path can be combined with other paths to solve the FLHS problem in a systematic way. This embodiment provides direct and key experimental evidence for proving the inventiveness (non-obviousness) of the present application.

[0167] This example, together with the dose-effect experiment, constitutes a solid data base supporting the patentability of the invention.

[0168] Six. Research on the synergistic mechanism of feed additives for preventing and treating fatty liver disease in laying hens based on multi-omics technology: Project goal: Apply transcriptomics and metabolomics technologies to reveal the internal mechanism of the multi-target synergistic effect of the additive (INV) at the molecular level and provide systematic biology evidence for its excellent efficacy.

[0169] Experimental design: See the previous experiment. Based on the completed animal experiment, liver tissue and serum samples were collected for multi-omics analysis.

[0170] Experimental design and sample collection: 1. Animal experiment: see the previous experimental design. Representative groups were selected: control group: basal diet.

[0171] Traditional regimen group: basal diet + choline chloride / betaine.

[0172] High-dose group of the invention: basal diet + 0.1% additive of the invention.

[0173] 2. Sample collection: At the end of the experiment, 6 chickens were randomly selected from each group, and after slaughter, the following samples were quickly collected: Liver tissue: part of it was quickly frozen in liquid nitrogen for transcriptomic analysis; part was used for lipid metabolite extraction.

[0174] Serum: for non-targeted metabolomics analysis.

[0175] 3. Multi-omics detection: Transcriptomics: liver tissue RNA extraction, mRNA sequencing, and analysis of differentially expressed genes.

[0176] Lipidomics: analysis of the composition of triglycerides, phospholipids, and fatty acids in liver tissue.

[0177] Serum non-targeted metabolomics: comprehensive analysis of changes in small molecule metabolites in serum.

[0178] Transcriptomic results: reveal the synergistic regulation at the gene expression level; Differential gene expression analysis, GO function, and KEGG pathway enrichment analysis were performed on liver tissue mRNA sequencing data.

[0179] 1. Core pathway regulation verification: fatty acid synthesis pathway: compared with the CON group, the expression levels of fatty acid synthase gene (FASN) and sterol regulatory element binding protein-1c (SREBP-1c) in the INV group were significantly down-regulated. This directly verifies the molecular mechanism of bile acid inhibiting de novo fatty acid synthesis by activating the FXR receptor.

[0180] Fatty acid oxidation pathway: The gene expression of carnitine palmitoyltransferase 1A (CPT1A) and peroxisome proliferator-activated receptor alpha (PPARa) in the INV group was significantly up-regulated. This provides the most direct molecular evidence for the core role of L-carnitine in promoting fatty acid beta-oxidation.

[0181] Antioxidant pathway: Antioxidant enzyme-related genes such as glutathione S-transferase (GST) and heme oxygenase-1 (HO-1) were significantly enriched and up-regulated in the INV group, and the nuclear factor E2-related factor 2 (Nrf2) pathway was significantly activated. This confirms the synergistic activation effect of the antioxidant network composed of NAC, rosmarinic acid, and selenium at the transcriptional level.

[0182] 2. Unique synergistic mode discovery: The transcriptome data found that the INV group could simultaneously positively regulate the fatty acid oxidation pathway (such as PPAR signaling) and negatively regulate the fatty synthesis pathway (such as Biosynthesis of unsaturated fatty acids). The TRAD group only had a slight effect on the fatty export-related genes, and could not achieve this "two-way precise regulation". This explains from the gene level why the effect of the present application is much better than that of the traditional scheme.

[0183] Metabolomics results: Capture the dynamic changes at the metabolite level; 1. Liver lipidomics analysis: Triglyceride (TG) species and content: The content of various long-chain triglycerides in the liver of the INV group was significantly lower than that of the CON group and the TRAD group, which is completely consistent with the result of the decrease in liver fat rate in the biochemical assay.

[0184] Phospholipid spectrum changes: The content of phosphatidylcholine (PC) in the liver of the INV group was significantly higher than that of the CON group. PC is a key component of VLDL synthesis, and this result supports the mechanism of lysophosphatidylcholine (LPA) accelerating the "export" of fat from the liver by promoting PC metabolism or VLDL assembly.

[0185] Fatty acid composition: The content of metabolites related to beta-oxidation (such as acylcarnitine) in the liver of the INV group changed, suggesting that fatty acid catabolism was more active.

[0186] 2. Serum non-targeted metabolomics analysis: Differential metabolite screening: In positive and negative ion modes, a large number of differential metabolites were found between the INV group and the CON group.

[0187] Pathway analysis: These differential metabolites were significantly enriched in primary bile acid biosynthesis, glycerophospholipid metabolism, and unsaturated fatty acid biosynthesis, which is highly consistent with the transcriptome results and the mechanism of the present application.

[0188] Potential biomarker discovery: The content of lysophosphatidylcholine (LPC16:0, 18:0) and other substances in the serum of the INV group was significantly increased. LPC is the precursor of LPA and an important component of lipoproteins. Changes in its level may reflect the improvement of liver fat transport status and can be used as a potential new biomarker to evaluate the effect of the product.

[0189] Multi-omics integrated analysis: Constructing a "gene-metabolite" synergistic network; Correlation analysis between differentially expressed genes and differentially metabolized substances in the transcriptome and metabolome to construct a "gene-metabolite" interaction network.

[0190] 1. Key regulatory hub confirmation: Network analysis shows that PPARa and FXR are two core regulatory nodes that connect a large number of downstream differential genes and metabolites. This indicates that the additive of the present application regulates these two core receptors, thereby triggering widespread changes in gene expression and metabolite levels downstream, ultimately achieving systematic improvement of lipid metabolism.

[0191] 2. Mechanism closed loop verification: Integrated analysis forms a clear evidence chain; Bile acids→activate FXR→down-regulate SREBP-1c / FASN (transcriptome)→reduce TG synthesis (lipidome); L-Left carnitine→activate PPARa→up-regulate CPT1A (transcriptome)→increase acylcarnitine and reduce TG (metabolome); Antioxidant network→activate Nrf2→up-regulate antioxidant enzymes (transcriptome)→reduce oxidative stress products (metabolome)→provide protection for the above metabolic processes; Conclusion: Through the integration of transcriptomic and metabolomic analysis, this study provides direct experimental evidence for the synergistic mechanism of the additive of the present application in preventing and treating fatty liver disease in laying hens from the system and molecular dimensions: 1. Confirmed the multi-target mechanism: The effectiveness of the four paths of "inhibiting synthesis, promoting oxidation, accelerating export, and antioxidant" was verified at both the gene and metabolite levels.

[0192] 2. Revealed the essence of synergy: Each component does not act in isolation, but through the regulation of core hubs such as PPARa, FXR, and Nrf2, a highly synergistic regulatory network is formed, thereby achieving "bidirectional regulation" of lipid metabolism.

[0193] 3. Discovery of potential biomarkers: Provides a new approach for subsequent product effect monitoring and rapid detection.

[0194] 4. Strengthen the technical synergy effect: Multi-omics data reveals the complexity and sophistication of its mechanism of action at the system level, strongly proving that the technical solution is not obvious to those skilled in the art, and produces unexpected synergistic technical effects based on deep biological understanding.

[0195] Table 15 Multi-omics technology verifies the mechanism of the invention Experimental summary:

[0196]

[0197]

[0198] Conclusion: 1. Data consistency: transcriptome data (gene expression down-regulation / up-regulation) is highly consistent with metabolome data (substrate / product content reduction / increase), forming a complete evidence chain from "cause" to "effect". For example: FASN gene down-regulation (transcriptome) → TG content reduction (lipidome). PPARa / CPT1A gene up-regulation (transcriptome) → acylcarnitine content increase (metabolome).

[0199] 2. Effectiveness: The change range of key indicators (such as mRNA expression change times, metabolite content change more than 50%) and extremely significant P value (usually less than 1E-05) strongly prove the strength and reliability of the intervention effect of the invention, which is not comparable to general minor improvements.

[0200] 3. Embodiment of synergy: The extreme activity of the PPAR pathway (pro-oxidation) and the activation of the FXR pathway (synthesis inhibition) occur simultaneously, achieving "bidirectional precise regulation" of liver fat metabolism.

[0201] Multi-omics network analysis shows higher network connectivity, providing a structural basis for "synergistic effect" at the system level, which is mutually confirmed by animal phenotype data (Bliss synergy index 71.4%).

[0202] 4. "Outstanding substantial features" and "significant progress" (i.e. creativity): Multi-omics data from gene expression (reason) to metabolite changes (result) level forms a complete, self-consistent evidence loop, strongly proving that the "decrease-transport-oxidation-protection" four-dimensional synergistic mechanism proposed by the invention is not only a theoretical hypothesis, but also an objective biological fact. These data reveal the complexity and sophistication of the combination of the invention at the system level, providing extremely critical high-level scientific evidence for proving that its technical solution has "outstanding substantial features" and "significant progress" (i.e. creativity) compared to traditional single-pathway solutions.

[0203] Seven, network pharmacology-based analysis of the mechanism of action of feed additive core components: Analysis object: synergistic feed additive (components: bile acids, lysophosphatidylcholine, L-carnitine, NAC, rosemary acid extract, selenium yeast) for preventing and treating fatty liver disease in laying hens; Analysis method: combination of network pharmacology (target prediction, network construction, pathway enrichment analysis) and experimental verification; Analysis background and purpose: Network pharmacology is a new discipline based on the "disease-gene-target-drug" interaction network, which systematically reveals the mechanism of multi-component drugs. This study applies this technology to: 1. Theoretical prediction: theoretically predict the potential key targets and signaling pathways of the six core components of the invention acting on fatty liver disease (FLHS) in laying hens.

[0204] 2. Mechanism interpretation: connect the computational prediction results with the "reducing burden-transporting-oxidizing-protection" four-dimensional synergistic mechanism of the invention, and provide theoretical support at the molecular level.

[0205] 3. Evidence of creativity: demonstrate the non-obviousness and overall synergy of the combination by showing the complex network synergy of components-targets-paths, providing supplementary evidence for patent creativity.

[0206] Materials and methods: 1. Core component active molecule screening: Obtain known active molecules of each component of the invention (such as CDCA, LPA, L-carnitine, NAC, rosemary acid, and selenomethionine) from databases such as PubChem and TCMSP.

[0207] 2. Potential target prediction: Use online servers such as SwissTargetPrediction and PharmMapper to predict the potential targets of the above active molecules.

[0208] 3. FLHS-related target collection: Use disease databases such as GenCards, OMIM, and DisGeNET to search for related disease targets of FLHS in laying hens / mammals using keywords such as "Fatty Liver Syndrome" and "Hepatic Steatosis".

[0209] 4. Network construction and analysis: Component-target network: Construct the interaction network of core components and predicted targets.

[0210] Protein interaction network: Import the intersection targets into the STRING database to construct a protein interaction network and screen for core targets.

[0211] Pathway enrichment analysis: GO function and KEGG pathway enrichment analysis of core targets were performed using tools such as DAVID, KOBAS, etc.

[0212] 5. Experimental verification correlation: Correlation analysis was performed between the network analysis results and the key indicators (hepatic fat rate, ALT / AST, GSH-Px, MDA, etc.) measured in the animal experiments of the application.

[0213] Results and analysis: 1. Core component-target network reveals multi-target characteristics; Network analysis showed that the six core components of the application jointly acted on a network containing 128 potential targets closely related to lipid metabolism, oxidative stress, and inflammatory response. The targets of each component overlapped and each had its own focus, showing a typical "multi-component-multi-target" characteristic.

[0214] Cholic acid (CDCA): The core targets were concentrated on nuclear receptors such as FXR and TGR5, verifying the molecular basis of its "inhibition of synthesis".

[0215] L-carnitine: It is significantly enriched in key enzymes and regulatory factors of fatty acid oxidation such as CPT1A and PPARa, supporting its "promotion of oxidation" function.

[0216] Antioxidant network (NAC / rosmarinic acid / selenium): It jointly acts on the KEAP1-Nrf2 pathway, apoptosis, and related antioxidant enzyme targets, forming a molecular network of "protection" mechanism.

[0217] 2. Pathway enrichment analysis confirms the systematic regulation mechanism; Table 16 KEGG pathway enrichment analysis results show that the core targets are significantly enriched in the following pathways (Top 10, P <0.01):

[0218] Analysis: Pathway analysis shows that the additive of the application does not randomly act on scattered targets, but systematically regulates the core signal network of FLHS occurrence and development, especially precisely intervenes the PPAR, AMPK, and FXR, which are three key hub pathways that regulate lipid metabolism globally.

[0219] 3. "Synergistic network" analysis as evidence of non-obviousness; Network complementarity: Comparing the component-target network of the application with a virtual network containing only methyl donors (choline) or a single bile acid, it was found that the network node connectivity of the application was higher and the network structure was more compact, indicating that each component formed a more complex regulatory network through the interaction between targets.

[0220] Key target coverage: The combination of the present application covers multiple key nodes in the FLHS disease network (such as PPARa, FXR, Nrf2), while any single component or traditional scheme can only cover part of the nodes. This synergistic coverage of key nodes in the disease is the structural basis for achieving the "1+1+1>3" synergistic effect.

[0221] 4. Network prediction and experimental results are mutually confirmed; Table 17 Network prediction and experimental results:

[0222] Innovative evaluation conclusion: 1. Non-obviousness: Network pharmacology analysis shows that the combination of components with different mechanisms focusing on "synthesis (FXR), export (LPA), oxidation (PPARa / CPT1A), and protection (Nrf2)" is not a routine technical means in the art. This combination is a creative design based on a deep understanding of the complex pathological mechanism of FLHS, which is far more complex and systematic than simple component superposition.

[0223] 2. Unexpected technical effect (synergistic effect): Computational analysis shows that the combination of the present application forms a highly interconnected and functionally complementary target regulation network. This explains why a synergistic effect rate of 71.4% was observed in animal experiments from the perspective of systems biology. The overall effect based on network synergy is unpredictable and unattainable by existing technologies that only focus on a single target or pathway.

[0224] Conclusion: Network pharmacology analysis provides strong theoretical basis and data support for the creativity (non-obviousness + significant progress) of the present patent from the "system-network-target" level. It clearly shows that the technical solution of the present application is an optimized combination based on innovative understanding of disease mechanisms, which can produce unexpected synergistic effects.

[0225] Experimental effect verification of core components in network pharmacology analysis in the synergistic prevention and treatment of fatty liver disease in laying hens: Relevant target: Confirm the computational predicted biological pathways with empirical data to strengthen the scientificity and credibility of the mechanism of action.

[0226] Network prediction and experimental verification of core component "L-carnitine (LCA)": 1. Network pharmacology prediction: Core target: CPT1A (carnitine palmitoyltransferase 1A), PPARa (peroxisome proliferator-activated receptor alpha).

[0227] Enrichment pathways: PPAR signaling pathway, Fatty acid degradation, AMPK signaling pathway.

[0228] Predicted function: As a key carrier, it promotes the entry of long-chain fatty acids into mitochondria for beta-oxidation, and is the core engine of fat catabolism.

[0229] 2. Experimental data verification: Dose-effect verification: Under the premise of fixed total amount of additives, with the increase of LCA proportion from 0% to 10%, the liver fat rate showed a significant dose-dependent decrease (from 4.6% to 3.4%), and the serum ALT activity was significantly improved (from 31.5 U / L to 25.1 U / L). The effect entered the platform period when the proportion of LCA was more than 10%.

[0230] Synergistic effect verification: Although LCA alone (single LCA group) has some effect (liver fat rate 7.10%), it is far inferior to the complete combination of the invention (INV group, liver fat rate 3.50%). This confirms the network prediction: although LCA is the core engine, its efficient operation depends on the favorable environment created by other components (such as antioxidant protection of mitochondrial function).

[0231] Key conclusion: Experimental data not only verifies the key role of LCA in promoting fat oxidation, but also proves that its efficacy is highly dependent on the synergistic system constructed by the invention, rather than isolated action.

[0232] Network prediction and experimental verification of core component "bile acid (CDCA)": 1. Network pharmacology prediction: Core targets: FXR (farnesol X receptor), TGR5.

[0233] Enrichment pathways: FXR / RXR activation pathway, Bile acid biosynthesis.

[0234] Predicted function: Activates FXR, down-regulates SREBP-1c expression, and thus inhibits de novo synthesis of liver fat (reduction source).

[0235] 2. Experimental data verification: Dose-effect verification: Bile acid proportion in the range of 15%-25% is effective, and 20% is the best point. When the proportion of bile acid is 0% (BA-0% group), the liver fat rate (5.2%) and ALT (35.8 U / L) are significantly different from the groups containing bile acid.

[0236] Functionality verification: The liver fat rate of bile acid alone (single BA group) is 6.80%, which is obviously but limited, indicating that its "synthesis inhibition" function needs to be coordinated with other mechanisms to maximize its benefits.

[0237] Key conclusion: The experiment confirms the effectiveness of bile acid in reducing the burden through the FXR pathway and determines its optimal working concentration in the invention. Its synergy with LPA (promoting export) achieves "opening up and saving" type of fat regulation.

[0238] Network prediction and experimental verification of the core component "antioxidant network (NAC + rosmarinic acid + selenium)": 1. Network pharmacology prediction: Core targets: Nrf2, KEAP1, GSR (glutathione reductase), GPX (glutathione peroxidase).

[0239] Enrichment pathway: Glutathione metabolism, Nrf2 signaling pathway.

[0240] Predicted function: Form a multi-level antioxidant defense: NAC as a GSH precursor to supplement the substrate, rosmarinic acid directly scavenges free radicals, and selenium as the active center of GSH-Px.

[0241] 2. Experimental data verification: Biochemical index verification: The GSH-Px activity (195 U / mg) of the high-dose group (IN-H) of the invention is extremely significantly the highest, and the MDA content (1.8 nmol / mg) is extremely significantly the lowest, directly proving the effectiveness of the antioxidant network.

[0242] Component necessity verification: The use of antioxidant combination alone (single AOX group) performs well in antioxidant indicators (such as MDA), but the effect is not good in core lipid-lowering indicators (liver fat rate 6.90%), proving that it cannot solve the problem of fat deposition alone.

[0243] Dose relationship verification: NAC (15-25%), rosmarinic acid extract (10-20%), and yeast selenium (1-3%) all show the best auxiliary effect within a specific proportion range.

[0244] Key conclusion: Experimental data perfectly confirm the synergistic liver protection of the "precursor (NAC) - enzyme (selenium) - scavenger (rosmarinic acid)" three-dimensional antioxidant network, which provides indispensable "escort" protection for the fat oxidation function of L- carnitine and the health of liver cells.

[0245] Network prediction and experimental verification of the core component "lyso- phosphatidylcholine (LPA)": 1. Network pharmacology prediction: Core targets: LPAR1-6 (lysophosphatidic acid receptors), PPARγ, ATGL (adipose triglyceride lipase).

[0246] Enriched pathways: PPAR signaling pathway, GPCR ligand binding, Lipid and atherosclerosis.

[0247] Predicted function: As a biological signal molecule, it promotes fat breakdown and assembly and secretion of very low-density lipoprotein (VLDL) by activating its receptors and nuclear receptors, solving the problem of fat "transport" obstacles.

[0248] 2. Experimental data verification: Dose-effect verification: The effect of lysophosphatidylcholine ratio is significant in the range of 10%-20%. When the proportion of LPA is 0% (LPC-0% group), the liver fat rate (5.0%) and ALT (34.2U / L) are significantly higher. When the proportion rises to 15%, the effect reaches a plateau, indicating that this concentration is sufficient to effectively activate the transport pathway.

[0249] Functional uniqueness verification: The use of LPA alone (single LPA group) shows better lipid-lowering effect (liver fat rate 6.20%), better than single bile acid group, which confirms the effectiveness of its "promoting transport" path. But its effect on improving liver function (ALT is 48.8U / L) is not as good as the complete combination of the invention, indicating that it needs to be coordinated with antioxidant components to protect liver cells.

[0250] Key conclusion: Experimental data confirms the key role of LPA in promoting liver fat "transport" and clearly defines its effective dose range. It and bile acid (synthesis inhibition) together constitute the core of the balance regulation of liver fat "in and out", and complement L- carnitine (promote decomposition).

[0251] Synergistic effect: Network prediction and Bliss model experimental verification: 1. Synergistic basis of network prediction: Network analysis shows that the core targets of each component are distributed in different key nodes of the fat metabolism and oxidative stress network, and these nodes are highly interconnected in the protein interaction network, which constitutes the structural basis for producing synergistic effect.

[0252] 2. Synergistic effect of experimental verification: Bliss independence model calculation shows that the synergistic effect rate of the composition of the invention on the core indicator of reducing liver fat rate is as high as 71.4%.

[0253] 3. Correlation analysis: This means that the excellent effect (such as a 48.5% reduction in liver fat rate) achieved by the present application has more than two-thirds of the additional gain from the interaction between components, rather than simple addition. This directly proves the existence and strong power of the "multi-target synergistic regulation" predicted by network pharmacology in reality.

[0254] Overall network robustness and experimental reproducibility analysis: 1. Network redundancy analysis: The "decompression-transportation-oxidation-protection" network constructed by the present application has high redundancy. For example, the PPAR pathway is regulated by L-carnitine (PPARa) and lysophosphatidylcholine (PPARy); the antioxidant network is composed of components with three different mechanisms. This multi-node, multi-path redundancy design makes the entire system more robust in the face of individual differences or environmental fluctuations.

[0255] 2. Experimental reproducibility verification: Multiple examples in the patent application (such as Example 4 and Example 5, dose gradient of Example 6) consistently reproduce the effect of the present application additive being significantly better than the control group and the traditional scheme under the same nutritional stress model. This high repeatability shown in different experimental batches and different detection indicators proves the stability and reliability of the network regulation effect from the empirical point of view.

[0256] Overall conclusion, from network prediction to market value transformation: 1. Strong evidence chain from "correlation" to "causality": This study successfully combines the "correlation" (component-target-pathway) predicted by network pharmacology with the "causality" (specific component leading to specific physiological index change) verified by animal experiments. This not only clarifies the mechanism, but also makes the technical solution of the present application go beyond empirical summary and is based on the scientific foundation of modern systems biology.

[0257] 2. Scientific basis for formula optimization: Network analysis reveals that each component acts on different but interrelated pathways, which explains why simple component stacking has limited effect, while the synergistic combination optimized by precise proportion can produce excellent results. Dose-effect experiments provide an accurate "navigation map" for this optimization.

[0258] 3. Inapparent: First, network pharmacology shows that the complexity of the combination far exceeds conventional thinking; second, experimental data show that its effect is not linear superposition but synergistic multiplication. That is, the present application cannot be derived from the prior art by those skilled in the art.

[0259] 4. Guide future product development: The established "network prediction-experimental verification" model can serve as a powerful tool for future development of similar functional additive products, improving R&D efficiency and success rate.

[0260] 5. Constructing scientific evidence system: through the integrated analysis of the invention for preventing and treating fatty liver disease of laying hens additive, from the network pharmacology prediction of the level of computational biology, to the dose effect of animal experiment, component comparison and synergistic effect quantification of the level of evidence, a closed loop, self-consistent and very convincing scientific evidence system is constructed.

[0261] The above merely provides the preferred embodiments of the present application, but the protection scope of the present application is not limited thereto, and any person skilled in the art can easily think of the changes or replacements within the technical range disclosed by the present application, which shall be covered within the protection scope of the present application.

Claims

1. A synergistic feed additive for preventing and treating fatty liver disease in laying hens, characterized in that, Includes the following components: Bile acids 15%-25%; Lysophosphatidylcholine 10%-20%; L-carnitine 5% - 15%; N-acetylcysteine ​​15%-25%; 10%-20% rosmarinic acid extract; Yeast selenium 1%-3%; Carrier margin; The carrier is one or more of water-soluble silica, rice husk powder, and dicalcium phosphate.

2. The synergistic feed additive for preventing and treating fatty liver disease in laying hens according to claim 1, characterized in that, The bile acids are derived from pig bile paste or poultry bile paste.

3. The synergistic feed additive for preventing and treating fatty liver disease in laying hens according to claim 1, characterized in that, The lysophosphatidylcholine content in the lysophosphatidylcholine is not less than 50%.

4. The synergistic feed additive for preventing and treating fatty liver disease in laying hens according to claim 1, characterized in that, The rosmarinic acid extract contains no less than 20% rosmarinic acid.

5. A method for preparing a feed additive, used to prepare the feed additive as described in any one of claims 1 to 4, characterized in that, Includes the following steps: Two-thirds of the carrier is fed into the main mixer as the base material and then the mixer is run. Add N-acetylcysteine, L-L-carnitine, rosmarinic acid extract, yeast selenium, and bile acids in sequence and slowly. Premix the lysophosphatidylcholine with the remaining one-third of the carrier in another mixer for 5 minutes to form a fluid mixture; Slowly add the premixed lysophosphatidylcholine-carrier mixture into the running main mixer; Close the mixer inlet and mix at 20-25 rpm for 25-30 minutes.

6. A feed, characterized in that, It comprises 99.9%-99.95% of a basal diet and 0.05%-0.10% of a feed additive as described in any one of claims 1 to 4; the basal diet comprises the following components: Corn 62.20; Soybean meal 24.50; Soybean oil 2.50; Stone powder 8.00; CaHPO4 1.30; NaCl 0.30; DL-methionine 0.15; L-Lys·HCl 0.05; Premix 1.00.

Images